title: Translation of anticancer efficacy from nonclinical models to the clinic.
abstract: Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm.
authors.affiliation: Clinical Pharmacology, Genentech, South San Francisco, California, USA.
authors.forename: M
authors.initials: M
authors.lastname: Stroh
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: D G
authors.initials: DG
authors.lastname: Duda
authors.affiliation: Translational Medicine Early Development, Janssen Research & Development, Radnor, Pennsylvania, USA.
authors.forename: C H
authors.initials: CH
authors.lastname: Takimoto
authors.affiliation: Pharmacokinetics, Dynamics and Metabolism-New Biological Entities, Pfizer, San Diego, California, USA.
authors.forename: S
authors.initials: S
authors.lastname: Yamazaki
authors.affiliation: Pharmacokinetics, Dynamics and Metabolism-New Biological Entities, Pfizer, San Diego, California, USA.
authors.forename: P
authors.initials: P
authors.lastname: Vicini
references.citation: AAPS J. 2013 Apr;15(2):354-66
references.pmid: 23250669
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6719-26
references.pmid: 18006773
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7917-23
references.pmid: 19047122
references.citation: Clin Cancer Res. 2005 Nov 1;11(21):7938-44
references.pmid: 16278419
references.citation: Nat Rev Drug Discov. 2007 Feb;6(2):115-20
references.pmid: 17159925
references.citation: Cell. 2013 Feb 28;152(5):1065-76
references.pmid: 23452854
references.citation: Clin Cancer Res. 2011 Apr 15;17(8):2074-80
references.pmid: 21349998
references.citation: Mol Cancer Ther. 2003 Feb;2(2):131-8
references.pmid: 12589030
references.citation: Mol Cancer Ther. 2008 Feb;7(2):407-17
references.pmid: 18281523
references.citation: J Clin Oncol. 2013 Jun 10;31(17):2205-18
references.pmid: 23669226